IgM anti-β 2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus

Journal of Rheumatology

Volumn 38, Issue 3, 2011, Pages 450-453

  Mehrani, Taraneh ^a,b   Petri, Michelle ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti 2 glycoprotein I; Antiphospholipid antibodies; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADULT; AFRICAN AMERICAN; AGED; ARTERY THROMBOSIS; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; HYPERTENSION; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENAL PROTECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTICARDIOLIPIN; BETA 2-GLYCOPROTEIN I; FEMALE; HUMANS; IMMUNOGLOBULIN M; KIDNEY; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MIDDLE AGED; YOUNG ADULT;

EID: 79952415556     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100650     Document Type: Article

References (39)

1. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine 1989;68:353-65. (Pubitemid 19286655)
2. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunological patterns of disease expression in a cohort of 1000 patients. Medicine 1993;72:113-24. (Pubitemid 23097765)
3. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990;112:682-98. (Pubitemid 20137178)
4. Merkel PA, Chang YC, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996;10:576-83. (Pubitemid 27150034)
5. Petri M. Epidemiology of the antiphospholipid syndrome. J Autoimmun 2000;15:145-51.
6. Tubach F, Hayem G, Marchand JL, Weber M, Palazzo E, de Bandt M, et al. IgG anti-β2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol 2000;27:1437-43. (Pubitemid 30354041)
7. Wong KL, Liu HW, Ho K, Chan K, Wong R. Anticardiolipin antibodies and lupus anticoagulant in Chinese patients with systemic lupus erythematosus. J Rheumatol 1991;18:1187-92.
8. Alarcon-Segovia D, Perez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992;21:275-86.
9. Loizou S, Samarkos M, Norsworthy PJ, Cazabon JK, Walport MJ, Davies KA. Significance of anticardiolipin and anti-beta2-glycoprotein I antibodies in lupus nephritis. Rheumatology 2000;39:962-8.
10. Piette JC, Cacoub P, Wechsler B. Renal manifestations of the antiphospholipid syndrome. Semin Arthritis Rheum 1994;23:357-66. (Pubitemid 24188342)
11. Piette JC, Kleinknecht D, Bach JF. Renal manifestations in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shonfeld Y, editors. The antiphospholipid syndrome. Boca Raton: CRC; 1996:169-81.
12. Bastian HM, Alarcon GS, Roseman JM, McGwin G Jr, Vilá LM, Fessler BJ, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. Rheumatology 2007;46:683-9. (Pubitemid 46523317)
13. Fofi C, Cuadrado MJ, Godfrey T, Abbs I, Khamashta MA, Hughes GR. Lack of association between antiphospholipid antibody and WHO classification in lupus nephritis. Clin Exp Rheumatol 2001;19:75-7. (Pubitemid 32203850)
14. Frampton G, Hicks J, Cameron JS. Significance of antiphospholipid antibodies in patients with lupus nephritis. Kidney Int 1991;39:1225-31.
15. Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S, et al. Antibodies to beta2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:1466-74. (Pubitemid 26314979)
16. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
17. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
19. Petri M, Rheinschmidt M, Whiting-O'Keefe Q, Hellmann D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and cardiolipin antibody level. Ann Intern Med 1987;106:524-31.
20. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with SLE. J Rheumatol 2002;29:2531-6. (Pubitemid 35416957)
21. Bombardier C, Gladman DD, Chang CH, Urowitz MB, and the Committee on Prognosis Studies in SLE. Development of the Disease Activity Index: the SLEDAI. Arthritis Rheum 1992;35:630-40.
22. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8. (Pubitemid 41785892)
23. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. Systemic lupus international collaborative clinics: Development of a damage index in systemic lupus erythematosus. J Rheumatol 1992;29:1820-1.
24. Petri M, Nelson L, Weimer F, Anderson D, Darlington T, Corash L. The automated modified Russell viper venom time test for the lupus anticoagulant. J Rheumatol 1991;18:1823-5.
25. Lakos G, Kiss E, Regeczy P, Tarján P, Soltész P, Zeher M, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I antibodies: importance of IgA isotype. Clin Exp Immunol 1999;117:574-9. (Pubitemid 29398308)
26. Amoroso A, Mitterhofer AP, Del Porto F, Garzia P, Ferri GM, Galluzzo S, et al. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol 2003;64:265-73. (Pubitemid 36197355)
27. Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies. Arthritis Rheum 2004;50:2569-79.
28. Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G, et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004;43:28-36. (Pubitemid 38049432)
29. Varela DC, Quintana G, Somers EC, Rojas-Villarraga A, Espinosa G, Hincapie ME, et al. Delayed lupus nephritis. Ann Rheum Dis 2008;67:1044-6. (Pubitemid 351956673)
30. Ishii Y, Nagasawa K, Mayumi T, Niho Y. Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis 1990;49:387-90. (Pubitemid 20170517)
31. Farrugia E, Torres VE, Gastineau D, Michet CJ, Holley KE. Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathologic study. Am J Kidney Dis 1992;20:463-71.
32. Perdiguero M, Boronat M, Marco P, Rivera F. The role of antiphospholipid antibodies in lupus nephropathy. Nephron 1995;71:35-9.
33. Natejumnong C, Ruangkanchanasetr P, Aimpun P, Supaporn T. Significance of antiphospholipid antibodies in lupus nephritis. J Med Assoc Thai 2006;89 Suppl 2:121-8.
34. Hill DS, Nochy D. Antiphospholipid syndrome in systemic lupus erythematosus. J Am Soc Nephrol 2007;18:2461-4. (Pubitemid 47378862)
35. Cohen D, Koopmans M, Kremer-Hovinga IC, Berger SP, Roos van Groningen M, Steup-Beekman GM, et al. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum 2008;58:2460-9.
36. Weidmann CE, Wallace DJ, Peter JB, Knight PJ, Bear MB, Klinenberg JR. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. Ann Rheum Dis 1988;49:387-90.
37. Perez Vazquez ME, Cabiedes J, Cabral RA, Alarcon-Segovia D. Decrease in serum antiphospholipid levels upon development of nephrotic syndrome in patients with systemic lupus erythematosus: relationship to urinary loss of IgG and other factors. Am J Med 1992;92:357-62.
38. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000;105:1731-40. (Pubitemid 30421754)
39. Silverman GJ, Srikrishnan R, Germar K, Goodyear CS, Andrews KA, Ginzler EM, et al. Genetic imprinting of autoantibody repertoires in systemic lupus erythematosus patients. Clin Exp Immunol 2008;153:102-16. (Pubitemid 351809346)